Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Aute leukemia working group (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT) study

American Journal of Hematology, EarlyView.
Source: American Journal of Hematology - Category: Hematology Authors: Source Type: research

Related Links:

Pediatric Transplantation, EarlyView.
Source: Pediatric Transplantation - Category: Transplant Surgery Authors: Source Type: research
Allogeneic stem cell transplantation (alloSCT) is a potentially curative therapeutic option for patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Disease relapse occurs in 35-45% of patients following alloSCT, and is the most frequent cause of treatment failure and mortality [1-4]. Moreover, relapse after alloSCT is associated with poor prognosis despite salvage chemotherapy, donor lymphocyte infusions, and/or second transplants [4].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
In a prospective, multi-center study of children undergoing hematopoietic stem cell transplantation (HSCT) for AML, we compared the efficacy of “Difference from Normal” (ΔN) flow cytometry approach for residual disease detection with assessment of Wilms Tumor 1 (WT-1) gene expression in a setting where the diagnostic specimen was not available.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
CONCLUSIONS: Interactions between leukemia cells and the bone marrow niche influence hematopoiesis, leukemogenesis, and chemotherapy resistance in AML and require ongoing study. Understanding the mechanisms that underlie these interactions will help identify rational niche-targeting therapies to improve treatment outcomes in AML patients. PMID: 29902132 [PubMed - as supplied by publisher]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research
Acute myeloid leukemia is a highly aggressive malignancy with a high morbidity rate, for which an accurate and rapid diagnostic is essential. Acute myeloid leukemia manifestations frequently include oral abnormalities. Still, there is a limited number of studies reporting the incidence of oral manifestations in acute leukemia, the prevalence of periodontal status and periodontal parameters in these patients. Our aim was to emphasize the importance of early recognition by the dental practitioners of oral cavity manifestations as signs of acute myeloid leukemia, so that prompt referral to the hematologists is being done, and...
Source: Medical Hypotheses - Category: Biomedical Science Authors: Source Type: research
Abstract Acute myeloid leukemia (AML) is a rapidly progressive, poor-prognosis malignancy arising from hematopoietic stem/progenitor cells. The long history of successful use of allogeneic hematopoietic cell transplantation (alloHCT) in AML indicates that this disease is immunoresponsive, leading to optimism that novel immunotherapies such as bispecific antibodies, chimeric antigen receptor T cells, and immune checkpoint inhibitors will generate meaningful disease control. However, emerging data on the immunoevasive tactics employed by AML blasts at diagnosis and at relapse indicate that optimism must be tempered ...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
AbstractRecently, an immunodeficiency syndrome caused by guanine-adenine-thymine-adenine 2 (GATA2) deficiency has been described. The syndrome is characterized by (i) typical onset in early adulthood, (ii) profound peripheral blood cytopenias of monocytes, B lymphocytes, and NK cells, (iii) distinct susceptibility to disseminated non-tuberculous mycobacterial (NTM) and other opportunistic infections (particularly human papillomavirus), and (iv) a high risk of developing hematologic malignancies (myelodysplastic syndromes (MDS); acute myeloid leukemias (AML)). Considerable clinical heterogeneity exists among patients withGA...
Source: Annals of Hematology - Category: Hematology Source Type: research
Mozaffar Aznab, Mansour KhazaieJournal of Cancer Research and Therapeutics 2018 14(3):703-705 Myeloid sarcoma can be occurred bofore acute myeloid leukemia, concomitantly, at relapse or after allogenic stem cell transplantation, rarely. In this investigation, we reported a 38-year-old woman with a history of AML relapsed 9 months after allo-SCT as an MS in the bilateral breast. She underwent bilateral mastectomy. The patient was a candidate for systemic chemotherapy. An intermediate dose of cytarabine with mitoxantrone was considered for the patient, and it was repeated at the specified intervals. Currently, the patient i...
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
Pediatric Blood&Cancer, EarlyView.
Source: Pediatric Blood and Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractWe have been using a combination of fludarabine/busulfan plus low-dose total body irradiation (TBI) as the reduced-intensity conditioning (RIC) regimen for patients age ≥ 60 years undergoing allogeneic hematopoietic cell transplantation (HCT) for myeloid malignancies. We retrospectively analyzed outcomes of 116 older patients (median age 64 years) who underwent HCT from 2006 to 2015 for myeloid malignancies, including acute myeloid leukemia (AML) in first com plete remission (CR1). On univariate analysis, overall survival (OS) for the cohort at 3 years was 33% (95% CI 25–42). Cumulati...
Source: Annals of Hematology - Category: Hematology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Hematology | Leukemia | Study | Transplants